VEGF inhibitors in glaucoma surgery
نویسندگان
چکیده
منابع مشابه
Anti-VEGF Agents and Glaucoma Filtering Surgery
Despite the introduction of various modern and minimally invasive glaucoma procedures, trabeculectomy is still considered to be the most effective treatment for glaucoma and the cornerstone of management for this potentially blinding condition. 1 It is a rather unique surgical procedure in medicine, because prevention of wound healing is crucial for surgical success. 2 Indeed, progressive fibro...
متن کاملUse of Anti-VEGF Agents in Glaucoma Surgery
A number of antivascular endothelial growth factor agents are currently available to treat various ocular conditions. These agents have similar, but distinct, biologic qualities and have been explored in the management of neovascular glaucoma and in glaucoma surgery. Several different delivery methods are described, and because these medications are routinely given as intraocular injections, so...
متن کاملGlaucoma Surgery in Pregnancy: A Case Series and Literature Review
AbstractGlaucoma management in pregnant patients is a real challenge, especially when the glaucoma is not controlled with medications. We report the results of 6 incisional glaucoma surgeries for the management of medically uncontrolled glaucoma patients during pregnancy. This retrospective, case series was conducted on the 6 eyes of 3pregnant patients with uncontrolled glaucoma using maximum t...
متن کاملSuprachoroidal Devices in Glaucoma Surgery
While conventional glaucoma filtration surgery provides excellent intraocular pressure (IOP) lowering effect, this comes at the expense of significant risks. As the physiology of the suprachoroidal space has become better understood, its potential as a source for aqueous drainage has generated significant interest. This has resulted in the creation of several suprachoroidal glaucoma devices wit...
متن کاملVEGF inhibitors in renal cell carcinoma.
The arrival of targeted therapies-vascular endothelial growth factor (VEGF) pathway inhibitors and mammalian target of rapamycin (mTOR) inhibitors-and programmed death 1 (PD-1) inhibitors has transformed the management of renal cell carcinoma (RCC). Once considered fatal, with a median survival of approximately 1 year, these agents have nearly tripled overall survival and have raised hopes of a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Ophthalmology journal
سال: 2016
ISSN: 2412-5423,1998-7102
DOI: 10.17816/ov9147-55